ArticleOrphanet journal of rare diseases2023

Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial.

Melissa P Wasserstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.